Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MSD
Japan Eyes Cutting Reimbursement For COVID-19 Drugs
Japan will end full reimbursement coverage for COVID-19 therapeutic drugs from October, after downgrading the status of the virus to the same level as seasonal flu in early May. As authorities discuss the possible coverage reduction, a larger than usual price cut may also be applied to Shionogi's oral COVID antiviral Xocova.
Japan Results Round-Up: Astellas, Daiichi Sankyo, Chugai Solid, Shionogi Hits New Heights
Amid positive ongoing forex impact, Astellas, Shionogi and Daiichi Sankyo logged solid fiscal years and Chugai has good growth in its first quarter, although some of the majors are expecting a decline in sales as demand due to COVID-19 wanes. Even so, Shionogi logged record results on the back on government procurement of its pandemic antiviral.
Learning From Danish Leaders: Openness, Engagement And Balance
Astute students of leadership can glean something from every approach. In Vivo asked five Danish biopharma executives to reflect on what characterizes Danish leadership. They shared insights on the defining features of a Danish approach, its pros and cons, and what lessons they can offer leaders from other countries.
Next Allergy Blockbuster? GI Innovation Shares Why It Is Confident
GI Innovation chairman and CEO B G Rhee talks about his ambitions for the Korean bispecific protein firm’s leading allergy and immuno-oncology pipeline assets and what is behind his confidence.
- Other Names / Subsidiaries
- Merck Sharpe & Dome
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.